These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Disposition and metabolism of the novel antihypertensive agent alacepril in rats. Matsumoto K; Miyazaki H; Fujii T; Yoshida K; Amejima H; Hashimoto M Arzneimittelforschung; 1986; 36(1):40-6. PubMed ID: 3513776 [TBL] [Abstract][Full Text] [Related]
10. Determination of captopril and its disulphide in biological fluids. Matsuki Y; Ito T; Fukuhara K; Nakamura T; Kimura M; Ono H J Chromatogr; 1982 Apr; 239():585-94. PubMed ID: 7047545 [TBL] [Abstract][Full Text] [Related]
11. Effect of probenecid on the disposition of captopril and captopril dimer in the rat. Drummer OH; Thompson J; Hooper R; Jarrott B Biochem Pharmacol; 1985 Sep; 34(18):3347-51. PubMed ID: 2994681 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. Onoyama K; Hirakata H; Tsuruda H; Ohchi N; Tomooka S; Motomura K; Omae T; Hayashi K; Fujishima M Clin Pharmacol Ther; 1985 Oct; 38(4):462-8. PubMed ID: 3899460 [TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous captopril in healthy men. Creasey WA; Morrison RA; Singhvi SM; Willard DA Eur J Clin Pharmacol; 1988; 35(4):367-70. PubMed ID: 3058486 [TBL] [Abstract][Full Text] [Related]
14. Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. Drummer OH; Jarrott B Biochem Pharmacol; 1984 Nov; 33(22):3567-71. PubMed ID: 6095854 [TBL] [Abstract][Full Text] [Related]
15. Metabolism of protein conjugate of desacetyl-alacepril and its effect on angiotensin converting enzyme in renal hypertensive rats. Matsumoto K; Nambu K; Fujii T; Takeyama K; Miyazaki H; Hashimoto M Arzneimittelforschung; 1986; 36(1):52-4. PubMed ID: 3006711 [TBL] [Abstract][Full Text] [Related]
16. Influence of chronic renal failure on captopril pharmacokinetics and clinical and biological effects in hypertensive patients. Giudicelli JF; Chaignon M; Richer C; Giroux B; Guedon J Br J Clin Pharmacol; 1984 Nov; 18(5):749-58. PubMed ID: 6095887 [TBL] [Abstract][Full Text] [Related]
17. [Effect of renal insufficiency on the pharmacokinetics of captopril and converting enzyme inhibition in the hypertensive patient]. Richer C; Chaignon M; Giroux B; Guédon J; Giudicelli JF Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1216-9. PubMed ID: 6098233 [TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. Kubo SH; Cody RJ Clin Pharmacokinet; 1985; 10(5):377-91. PubMed ID: 2994938 [TBL] [Abstract][Full Text] [Related]
19. Impairment of captopril bioavailability by concomitant food and antacid intake. Mäntylä R; Männistö PT; Vuorela A; Sundberg S; Ottoila P Int J Clin Pharmacol Ther Toxicol; 1984 Nov; 22(11):626-9. PubMed ID: 6389377 [TBL] [Abstract][Full Text] [Related]
20. Metabolism of captopril-L-cysteine, a captopril metabolite, in rats and dogs. Kripalani KJ; Dean AV; Migdalof BH Xenobiotica; 1983 Dec; 13(12):701-5. PubMed ID: 6372264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]